welcome
Reuters

Reuters

Health

Health

GSK resolves patent lawsuit against Pfizer over RSV vaccines

Reuters
Summary
Nutrition label

76% Informative

GlaxoSmithKline and Pfizer have agreed to end a lawsuit that alleged Pfizer 's respiratory syncytial virus ( RSV ) vaccine Abrysvo violated GSK 's patent rights in its competing RSV shot Arexvy.

The respiratory disease typically causes cold-like symptoms, but it is also a leading cause of pneumonia in toddlers and older adults.

GSK , Pfizer and Moderna have developed RSV shots approved by the U.S. Food and Drug Administration .

VR Score

87

Informative language

94

Neutral language

21

Article tone

formal

Language

English

Language complexity

58

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

short-lived

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links

Small business owner?

Otherweb launches Autoblogger—a revolutionary way to bring more leads to any small business, using the power of AI.